Fundraising Fox

Crystalystx

San Diego, US · Founded 2025 · 23 employees on LinkedIn · 6 known investors

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.

BiotechHealthtechMedical Devices

Founders & leadership

JMJames Mackay
James MackayinPresident & Chief Executive Officer
NB
Nihar BhaktainChief Medical Officer
AR
Ashwin RaminChief Operating Officer
DR
DeAnne ReidinChief Administrative Officer

Investors · 6

Catalys Pacific✓ verifiedTokyo
Novo Holdings✓ verifiedCopenhagen · $1.1M – $54M
AN Venture PartnersTokyo
Frazier Life SciencesPalo Alto
Lightstone VenturesPortola Valley
Longwood FundBoston

Frequently asked questions

What does Crystalystx do?
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid. Its lead investigational therapy is a selective URAT1 inhibitor designed to lower serum uric acid by targeting renal urate reabsorption pathways.
Who are Crystalystx's investors?
Crystalystx's investors include Catalys Pacific, Novo Holdings, AN Venture Partners, Frazier Life Sciences, Lightstone Ventures, Longwood Fund.
Where is Crystalystx headquartered?
Crystalystx is headquartered in San Diego, US.